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Setting public health priorities requires precise estimation of the burden of disease,  including disease-
speciﬁc medical expenditure.  Information on multiple and ruled-out diagnoses on health insurance 
claims (HICs) has been ignored in traditional analyses of disease-speciﬁc medical expenditures in 
Japan.  This study reviewed 448 inpatients with at least one diagnosis of sepsis on their HICs,  who 
were insured by corporate health insurance organizations making claims on services provided from 
April 2006 to March 2007 in Japan.  Subjects in whom sepsis-related diagnoses were speciﬁed as “ruled-
out” were compared with subjects in whom sepsis-related diagnoses were classiﬁed as “not-ruled-out” 
(i.e.,  subjects in whom sepsis was considered possibly or likely present).  Direct medical expenditure,  
length of stay (LOS),  cost per day,  cost of antibiotics,  and proportion of administered cephalosporin 
and carbapenems were signiﬁcantly higher in subjects classiﬁed as not-rule-out.  When using health 
insurance claims in Japan,  the statistics of medical expenditures and LOS are inﬂuenced by procedures 
performed to rule out a diagnosis,  as well as those performed to treat a conﬁrmed diagnosis of sepsis.
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etting public health priorities requires precise 
estimation of the burden of disease,  including 
disease-speciﬁc medical expenditures.  However,  there 
are some technical limitations for estimating disease-
speciﬁc medical expenditures in Japan [1-5].  In 
Japan,  health insurance coverage is universal and was 
originally based on fee-for-service reimbursement.  In 
2003,  DPC/PDPS (Diagnosis Procedure Combina-
tion/Per-Diem Payment System) was introduced in 
hospitals for acute inpatient care.  However,  the fee-
for-service reimbursement system for outpatient care 
and hospitals for chronic inpatient care has continued 
without major change.  In order to claim reimburse-
ment for the costs of healthcare services provided in 
a given calendar month,  each healthcare provider 
submits health insurance claims (HICs) to the Health 
Insurance Claims Review & Reimbursement Services 
(HICRRS) or to the National Health Insurance 
Organization (NHIO),  depending on the patientʼs spe-
ciﬁc health insurance plan.  The HICRRS or NHIO 
investigates the HICs to determine the patientsʼ eligi-
bility for coverage and whether the healthcare ser-
vices provided meet the regulations of the reimburse-
ment rules deﬁned by the Ministry of Health,  Labour 
and Welfare.  After the investigations,  the HICRRS 
or NHIO then sends the HICs to the insurers.
　 The data ﬁelds recorded on the HICs are identical 
regardless of the insurance provider [6].  The statis-
tics concerning medical expenditures in Japan,  such as 
those from the Estimation of National Medical 
Expenditure,  Social Insurance Claims Survey,  or 
National Health Insurance Medical Beneﬁt Surveys,  
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are based on data from these HIC reports.  The actual 
medical expenditures and length of stay (LOS) for 
inpatients hospitalized for 2 or more months has not 
yet been estimated in Japan because conventional sta-
tistics using HIC data in Japan have been based on the 
analysis of one monthʼs HICs only (the month of May) 
[4,  7].  Statistics concerning disease-speciﬁc medical 
expenditures in Japan are based on broad disease 
categories subdivided from the chapters in the 
International Statistical Classiﬁcation of Diseases and 
Related Health Problems,  10th Revision (ICD-10).  
For example,  medical expenditures for sepsis alone 
have not yet been estimated because sepsis is classi-
ﬁed under the broad category of “other infectious 
diseases and parasitic diseases. ”
　 Owing to the regulations of reimbursement in 
Japan,  health care providers are required to submit a 
single HIC combining all health care services for an 
individual rendered by the provider in a given calendar 
month; thus,  most HICs contain more than one diag-
nosis [3,  5,  8].  As a result of technical limitations 
for handling all of the information recorded on an HIC,  
it is common to select only one principal diagnosis 
from an HIC and ignore the existence of additional 
diagnoses when estimating disease-speciﬁc medical 
expenditures.
　 Furthermore,  HICs contain not only conﬁrmed 
diagnoses,  but also diagnoses that are unconﬁrmed or 
disproved.  Each clinical procedure must be justiﬁed 
by a corresponding diagnosis; as a result,  ruled-out 
diagnoses are included in the HICs to ensure reim-
bursement for the diagnostic tests,  even when the 
results show that the suspected diseases are not pres-
ent.  Thus,  estimations of disease-speciﬁc medical 
expenditures in Japan include expenditures on patients 
in whom diseases are suspected but not present 
because information provided on the HICs does not 
distinguish between conﬁrmed diagnoses and ruled-out 
diagnoses [9,  10].
　 Sepsis is a life-threatening disease and requires 
signiﬁcant medical resources for treatment [11-15].  
Blood cultures are commonly performed to conﬁrm or 
rule out sepsis in patients hospitalized due to cancer 
or trauma,  as nosocomial bloodstream infections can 
cause complications that result in a substantial increase 
in hospital LOS and total cost of care [13].  Such 
procedures to rule out sepsis are included in HICs to 
ensure reimbursement for these clinical procedures,  
even if sepsis is not conﬁrmed in the patients.  When 
conducting an analysis of expenditures speciﬁc to a 
condition like sepsis,  it is important to distinguish 
between procedures performed to rule out the diagno-
sis,  and those that are performed to treat a conﬁrmed 
diagnosis.
　 This study aimed to more accurately describe the 
medical expenditures,  LOS,  and clinical procedures 
performed on patients whose HICs include the diagno-
sis of sepsis.  By including information on multiple and 
ruled-out diagnoses reported on the HICs,  which have 
previously been ignored in the statistics of disease-
speciﬁc medical expenditure in Japan,  our study was 
able to diﬀerentiate between procedures performed to 
rule out the diagnosis of sepsis versus those per-
formed due to a conﬁrmed diagnosis of sepsis.
Methods
　 Study setting. This study investigated all inpa-
tient HICs submitted to an employee health insurance 
organization from April 2006 to March 2007.  The 
employee health insurance organizations used in this 
study were the same ones we examined in our previous 
reports [8-10].  The number of insured persons and 
their dependents was 330,195 as of March 31,  2007.  
We identiﬁed 448 inpatients with at least one HIC 
including a diagnosis classiﬁed as sepsis.  We collected 
data on medical expenditures,  LOS,  cost of antibiot-
ics,  injected cephalosporin and carbapenems,  and all 
diagnoses listed on the HICs.  If a patient was hospi-
talized for 2 or more months,  all the inpatient HICs 
were collected and the data were combined.
　 Deﬁnition of ruled-out diagnosis for sepsis 
group. In this study,  sepsis is deﬁned as a diag-
nosis of one of the following according to the ICD-
10: A40 (Streptococcal sepsis),  A41 (Other sepsis),  
P36 (Bacterial sepsis of newborn),  and T81.4 
(Infection following a procedure,  not elsewhere clas-
siﬁed).  In accordance with the reimbursement rules of 
the Japanese health insurance system,  we classiﬁed 
each diagnosis as either a ruled-out diagnosis or con-
ﬁrmed diagnosis,  based on whether or not the diagno-
sis was marked “ruled-out diagnosis” on the HIC [9,  
10].  If all of a patientʼs diagnoses for sepsis were 
ruled-out diagnoses,  we classiﬁed the patient under 
the “ruled-out” group.  These were the patients in 
whom sepsis was conﬁrmed not to be present.  
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However,  if a patient had at least one diagnosis of 
sepsis not marked “ruled-out diagnosis, ” we classiﬁed 
the patient under the “not-ruled-out” group.  These 
were the patients in whom sepsis was presumably 
conﬁrmed to be present.
　 Statistical analysis. Total medical expendi-
tures,  cost per day,  and cost of antibiotics were 
expressed in Japanese yen (¥100＝US$1.08 or €0.83,  
as of February 26,  2013).  We conducted logarithmic 
transformation for total medical expenditures,  LOS,  
cost per day,  and cost of antibiotics before conducting 
the Studentʼs t-test.  Studentʼs t-test was used to com-
pare the various parameters for the ruled-out and not-
ruled-out sepsis groups.  The χ2 test was used for 
categorical data.  A two-sided p-value of ＜0.05 was 
considered to be statistically signiﬁcant.  All analyses 
were performed using the IBM SPSS Statistics 
Version 19 (International Business Machines Corpo-
ration,  Armonk,  NY,  USA).
　 Personally identiﬁable information was removed 
prior to the analysis using the MediC4 encoding sys-
tem (Japan Medical Data Center Co.  Ltd.,  Tokyo,  
Japan) [16].  The study protocol was approved by the 
Ethics Committee of Fukuoka University.
Results
　 Table 1 shows data on sex,  age,  LOS,  and direct 
medical expenditures related to the diagnosis of sep-
sis.  There were slightly more patients with ruled-out 
diagnoses (260; 58.0ｵ) than with not-ruled-out diag-
noses for sepsis (188; 42.0ｵ).  The proportion of male 
subjects in the ruled-out group and the not-ruled-out 
group were 63ｵ (164/260) and 57ｵ (107/188),  
respectively,  with no statistical diﬀerence.  The aver-
age age of subjects in the ruled-out group was lower 
than that of subjects in the not-ruled-out group,  but 
the diﬀerence was not signiﬁcant.  The average LOS 
and amount of direct medical expenditures for subjects 
in the not-ruled-out group were more than twice as 
high as those for subjects in the ruled-out group,  and 
these diﬀerences were statistically signiﬁcant (p＜
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Table 1　 Sex,  Age,  Length of Stay (LOS),  and direct medical expenditures for subjects in whom sepsis was and was not ruled out
Ruled-Out Group Not-Ruled-Out Group p-value
Number of subjects 260 188
Sex
　Male 164 (63.1%) 106 (56.4%) 0.153
　Female 96 (36.9%) 82 (43.6%)
Age
　Minimum 0 1
　Median 23.5 31.5
　Maximum 90 95
　Mean (±SD) 28.1 (±25.2) 30.7 (±27.1) 0.298
LOS (days)
　Minimum 3 3
　Median 10 27.5
　Maximum 335 345
　Mean (±SD) 25.3 (±39.5) 56.8 (±69.0) ＜0.001
Direct medical expenditure
　Minimum 73,860 81,460
　Median 330,585 1,028,855
　Maximum 14,805,550 23,827,580
　Mean (±SD) 900,873 (±1,528,472) 2,643,084 (±3,705,097) ＜0.001
Cost per day
　Minimum 13,187 7,834
　Median 32,966 38,856
　Maximum 215,234 262,172
　Mean (±SD) 38,083 (±24,420) 47,351 (±32,311) ＜0.001
Medical expenditures are expressed in Japanese yen (¥).
SD indicates standard deviation.
0.001).  The average cost per day for subjects in the 
not-ruled-out group was 25ｵ higher than that for 
subjects in the ruled-out group,  and the diﬀerence was 
statistically signiﬁcant (p＜0.001).
　 Table 2 shows the cost of antibiotics (injected 
cephalosporin and injected carbapenem) associated 
with a diagnosis of sepsis.  Antibiotics were adminis-
tered prophylactically to all patients,  regardless of 
type of sepsis diagnosis (ruled-out or not-ruled-out).  
The average cost of all antibiotics given to subjects in 
the not-ruled-out group (¥46,633.70) was 66ｵ higher 
than that of subjects in the ruled-out group 
(¥28,034.00); the diﬀerence was statistically signiﬁ-
cant.
　 Cephalosporin was administered to a signiﬁcantly 
higher proportion of subjects in the not-ruled-out 
group (149; 79.3ｵ) than the ruled-out group (184;  
70.7ｵ) (p＝0.042).  The average cost for subjects in 
the not-ruled-out group who were administered cepha-
losporin (¥23,142.90) was 60ｵ higher than that of 
subjects in the ruled-out group (¥14,334.30).  However,  
the diﬀerence was not statistically signiﬁcant (p＝
0.194).
　 Carbapenems were administered to a signiﬁcantly 
higher proportion of subjects in the not-ruled-out 
group (59; 31.4ｵ) than in the ruled-out group (31;  
11.9ｵ) (p＝0.001).  However,  the average cost of 
administered carbapenems for subjects in the not-
ruled-out group was not signiﬁcantly diﬀerent from 
that of subjects in the ruled-out group (p＝0.590).
Discussion
　 This study investigated 448 inpatients with at least 
one HIC that included a diagnosis classiﬁed as sepsis,  
and the associated medical expenditures,  LOS,  cost 
per day,  and cost of antibiotics.  Our analysis yielded 
2 major ﬁndings.  First,  we found that the average 
direct medical expenditure and cost per day for sub-
jects in whom sepsis was not ruled out were signiﬁ-
cantly higher than for subjects in whom sepsis was 
ruled out.  Second,  we found that the amount and 
average total cost of antibiotics administered was 
higher in subjects in whom sepsis was not ruled out.
　 This is the ﬁrst study in Japan that reveals diﬀer-
ences in procedures and medical expenditures for 
inpatients with and without a ruled-out diagnosis for 
sepsis.  Japanʼs health insurance system is originally 
based on a fee-for-service reimbursement model,  the 
rules of which dictate that each clinical procedure 
must be justiﬁed by a corresponding diagnosis.  As a 
result,  ruled-out diagnoses are often included in the 
4 Acta Med.  Okayama　Vol.  68,  No.  1Tanihara et al.
Table 2　 Cost of antibiotics for subjects in whom sepsis was and was not ruled out
Ruled-Out Group Not-Ruled-Out Group p-value
All antibiotics
　Number of patients 260 (100%) 188 (100%) NA
　Minimum 174 148
　Median 11,096 16,688
　Maximum 1,245,776 1,092,749
　Mean (±SD) 28,034 (±91,399) 46,634 (±100,337) ＜0.001
Cephalosporin for injection
　Number of patients 184 (70.7%) 149 (79.3%) 0.042
　Minimum 492 312
　Median 9,486 10,752
　Maximum 131,093 413,261
　Mean (±SD) 14,334 (±17,943) 23,143 (±45,412) 0.194
Carbapenems for injection
　Number of patients 31 (11.9%) 59 (31.4%) ＜0.001
　Minimum 2,455 564
　Median 20,628 21,384
　Maximum 119,772 138,600
　Mean (±SD) 25,254 (±25,128) 29,509 (±27,251) 0.590
Medical expenditures are expressed in Japanese yen (¥).
SD indicates standard deviation.
HIC to ensure reimbursement for these clinical proce-
dures,  even when results show that the suspected 
diseases are not present [9,  10].  Since most HICs 
were being submitted on paper until recently,  techni-
cal limitations had prevented analystsʼ ability to distin-
guish between ruled-out diagnoses and conﬁrmed 
diagnoses.  As such,  estimates of disease-speciﬁc 
medical expenditures in Japan may not have been 
accurate because they did not account for these diﬀer-
ences [4,  7].  Only since April 2011 have medical 
facilities been mandated to provide HIC data through 
online systems.  Such computerization will facilitate 
the analysis of information from HICs,  including 
information that has not yet been available by the 
conventional method.
　 Compared to the conventional estimation of dis-
ease-speciﬁc medical expenditures [4,  7],  this study 
has 2 strengths.  First,  this study investigated all the 
diagnoses classiﬁed as “sepsis” in the HICs studied.  
Even though multiple diagnoses may be mentioned on 
the claim,  it is common for researchers to select only 
one principal diagnosis from an HIC in their analyses 
of disease-speciﬁc medical expenditures [8].  Classiﬁ-
cation by principal diagnosis cannot avoid bias,  in that 
some diagnoses are more likely to be chosen as princi-
pal diagnoses than others; for example,  hypertensive 
diseases (ICD-10: I10-15) are more likely than other 
diseases of endocrine,  nutrition and metabolism (ICD-
10: E15-90) to be chosen as a principal diagnosis [3,  
8].  These biases may contribute to over-estimation of 
health care expenditures for some diseases and under-
estimation of expenditures for others.  The HICs can 
represent a suitable data source if all diagnoses listed 
are analyzed,  as has been demonstrated in studies 
evaluating measles surveillance [17] and in the 
assessment of the quality of care for diabetes patients 
[18].
　 The next is that diagnoses were classiﬁed accord-
ing to the disease categories of the ICD-10.  In most 
Japanese statistics on medical expenditures,  sepsis is 
classiﬁed under “other infectious diseases and para-
sitic diseases” based on the broad groups of disease 
categories subdivided from the chapters in the ICD-
10,  making it diﬃcult to estimate the medical expen-
ditures for sepsis alone.  The classiﬁcation of diagno-
ses according to the speciﬁc disease category of the 
ICD-10 should be utilized in the analysis of disease-
speciﬁc medical expenditures.
　 This study has 2 major limitations.  First,  the 
subjects were limited to patients covered under 
employee health insurance; therefore,  data from the 
HICs analyzed in this study are not necessarily repre-
sentative of the total population in Japan.  However,  
we can assume that the current results are broadly 
applicable,  since health insurance coverage in Japan is 
universal,  with a uniform claims format and fee sched-
ule.
　 Second,  the comorbid diagnoses included in the 
HICs are not uniﬁed for all the patients; thus,  the 
severity of the patientsʼ diagnoses was not taken into 
account in this study.  For instance,  the LOS and cost 
of care for cancer patients with severe sepsis are 
around 3 times higher than those of cancer patients 
without severe sepsis [11].  The information on HICs 
in Japan is limited to diagnoses,  medical procedures 
used,  and names of prescribed drugs.  As test results 
are not provided in the HICs,  this study was unable to 
directly evaluate the severity of the diagnoses of the 
sample population.  In addition,  evaluations of total 
medical expenditures,  LOS,  cost per day,  and cost of 
antibiotics associated with the diagnosis of sepsis 
using laboratory-conﬁrmed blood-stream infection 
based on international guidelines [19] or isolation of 
a pathogen from blood culture bottle [13],  with 
severity of sepsis,  or with comorbid diagnoses [11,  
15,  20],  still await further investigation.
　 In conclusion,  we revealed diﬀerences in medical 
expenditures and procedures for inpatients in whom 
sepsis was and was not ruled out.  Our analyses pro-
vide objective justiﬁcation for utilizing information 
ignored by conventional methods of estimating disease-
speciﬁc medical expenditures in Japan.
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